K
Kristina A. Butler
Researcher at Mayo Clinic
Publications - 46
Citations - 583
Kristina A. Butler is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 10, co-authored 34 publications receiving 356 citations. Previous affiliations of Kristina A. Butler include University of Insubria.
Papers
More filters
Journal ArticleDOI
Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
S. John Weroha,Marc A. Becker,Sergio Enderica-Gonzalez,Sean C. Harrington,Ann L. Oberg,Matthew J. Maurer,Sarah E. Perkins,Mariam M. AlHilli,Kristina A. Butler,Sarah McKinstry,Stephanie R. Fink,Robert B. Jenkins,Xiaonan Hou,Kimberly R. Kalli,Karin Goodman,Jann N. Sarkaria,Beth Y. Karlan,Amanika Kumar,Scott H. Kaufmann,Lynn C. Hartmann,Paul Haluska +20 more
TL;DR: This is the largest known living tumor bank of patient-derived, ovarian tumorgraft models that can be applied to the development of personalized cancer treatment and response to platinum chemotherapy correlates with the source patient.
Journal ArticleDOI
Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts
Kristina A. Butler,Xiaonan Hou,Marc A. Becker,Valentina Zanfagnin,Sergio Enderica-Gonzalez,Daniel W. Visscher,Kimberly R. Kalli,Piyawan Tienchaianada,Paul Haluska,S. John Weroha +9 more
TL;DR: Ovarian cancer PDXs which developed human lymphomas are characterized and investigators utilizing PDX models for research should routinely monitor for lymphoproliferative tumors and consider implementing methods to suppress their growth.
Journal ArticleDOI
Adoption of Minimally Invasive Surgery and Decrease in Surgical Morbidity for Endometrial Cancer Treatment in the United States.
Jvan Casarin,Francesco Multinu,Daniel S. Ubl,Sean C. Dowdy,William A. Cliby,Gretchen E. Glaser,Gretchen E. Glaser,Kristina A. Butler,Kristina A. Butler,Fabio Ghezzi,Fabio Ghezzi,Elizabeth B. Habermann,Andrea Mariani,Andrea Mariani +13 more
TL;DR: The widespread adoption of minimally invasive surgery is associated with substantial decreases in 30-day morbidity, readmission, and reoperation for women treated for endometrial cancer in the United States.
Journal ArticleDOI
The LACC Trial and Minimally Invasive Surgery in Cervical Cancer
Ignace Vergote,Javier F. Magrina,Vanna Zanagnolo,Paul M. Magtibay,Kristina A. Butler,Antonio Gil-Moreno,Berta Diaz Feijoo,Rainer Kimmig,Michel Canis,Nicholas Bourdel,Thomas Ind,Rick Estape,Jan Persson,Peter C.W. Lim,Pluvio J. Coronado,Jordi Ponce,Eric Lambaudie,Toon Van Gorp,Angelo Maggioni,Fabrice Narducci,Els Van Niewwenhuysen,Philippe Van Trappen +21 more
Journal ArticleDOI
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
Gerardo Colon-Otero,Valentina Zanfagnin,Xiaonan Hou,Nathan R. Foster,Erik Asmus,Andrea E. Wahner Hendrickson,Aminah Jatoi,Matthew S. Block,Carrie L. Langstraat,Gretchen E. Glaser,Tri A. Dinh,Matthew W. Robertson,John K. Camoriano,Kristina A. Butler,John A. Copland,S. John Weroha +15 more
TL;DR: Ribociclib and letrozole have promising clinical activity in relapsed ER-positive OC and EC, particularly in LGSOC and relapsedER-positive grade 1 and 2 EC.